Cabaletta Bio is trading at $2.36, down 5.52%, after opening-session weakness on September 23, 2026, amid broader market pressure.

  • The Nasdaq is down 1.10% and the S&P 500 is down 0.55%, as rising oil prices and Treasury yields pressure risk assets.
  • No new company-specific announcement appears on Cabaletta Bio’s official release list after the September 1 investor-conference notice.
  • Biotech remains stronger overall, limiting support for a sector-driven explanation.